Preclinical safety studies of cefmetazole.
In order to assess the safety of cefmetazole, preclinical multiple-dose parenteral studies, varying from one to three months in length, were conducted in Sprague-Dawley rats and beagle dogs. Although the largest doses used were in multiples of several times the weight-adjusted doses intended for humans, cefmetazole was generally well tolerated. The principal adverse effect noted in the adult rats receiving the largest doses (2000 and 2500 mg/kg/day) of cefmetazole was slight elevation of serum alanine aminotransferase. Infant rats injected subcutaneously with 300 mg/kg/day or more of cefmetazole for 35 consecutive days had reversible reductions in testicular weight and maturation of spermatogenesis, but not lasting discernible effect on reproductive function. The most consistent effects of longterm multiple dosing with cefmetazole in dogs consisted of vomiting and retching during dosing and reversible haematological changes (mild regenerative anaemia, positive Coombs' test, clinically-silent thrombocytopenia) in a number of the dogs. These findings supported the interpretation that cefmetazole was acceptably safe for clinical studies in humans.
Moe
J B
JB
Upjohn Company, Kalamazoo, Michigan 49001.
Piper
R C
RC
Tanase
H
H
Sotani
K
K
Manabe
J
J
D000818:Animals; D000831:Animals, Newborn; D015311:Cefmetazole / Q000633:toxicity*; D004285:Dogs; D008297:Male; D009929:Organ Size; D051381:Rats; D011919:Rats, Inbred Strains; D013737:Testis / Q000187:drug effects; D013777:Tetrazoles / Q000633:toxicity
D013777:Tetrazoles; C038625:1-N-methyl-5-thiotetrazole; D015311:Cefmetazole